Open Pharma is proud to announce that Alfasigma has become the latest Member of Open Pharma.
Open Pharma aims to drive positive change in the communication of research funded by the pharmaceutical industry, with a focus on improving the transparency, accountability, accessibility and discoverability of published research.
Alfasigma is a leading Italian pharmaceutical company dedicated to improving people’s health and quality of life by offering caregivers and healthcare personnel therapeutic solutions.
Today’s announcement that Alfasigma has become an official Member of Open Pharma reinforces its commitment to leading a change in healthcare communications, a vision shared by all at Open Pharma. Together, Alfasigma and the other Members and Supporters of Open Pharma will continue to work towards a future in which the highest quality, peer-reviewed evidence is available and accessible to anyone who needs it, anywhere in the world.
As Joana Osório, Communications Team Leader at Oxford Pharmagenesis and Project Lead of Open Pharma, explains, “Collaboration is essential to drive change in the communication of pharma-sponsored research. We’re delighted to welcome Alfasigma – a company with such a strong focus on leading change – to Open Pharma.”
Alfasigma joins the 18 existing Members and Supporters of Open Pharma from across the publishing, medical communications and pharmaceutical industries (Members: AstraZeneca, Boehringer Ingelheim, Gilead, GSK, Johnson & Johnson, Lilly, Novartis, Novo Nordisk, Oxford PharmaGenesis, Pfizer, Takeda, UCB; Supporters: Astellas, Bristol Myers Squibb, Ipsen, Roche, Sage and Taylor & Francis).
About Open Pharma
Open Pharma, a multi-sponsor collaboration facilitated by Oxford PharmaGenesis, is driving transparent communication of pharma-sponsored research. Open Pharma is working to improve the pharma publications model by connecting pharma with innovations in publishing to increase transparency and access to research outputs. Our four core goals are:
- Transparency – aiming to increase access to scientific information to advance medical science and improve patient care
- Accountability – aiming to increase accountability and transparency and reduce administrative burden
- Accessibility – aiming for faster and wider dissemination of results, increased citations and use of results
- Discoverability – aiming to have targeted content for each user group available from a single point
For more information contact: OxfordProject@pharmagenesis.com
About Alfasigma
Alfasigma S.p.A is one of Italy’s leading pharmaceutical companies with strong international positioning. The Group has a worldwide presence in over 100 countries where about 4000 people work in research, development, production and distribution. Its historical headquarters is in Bologna, to which is added Milan, while the production sites are: in Italy, in Pomezia (RM), Alanno (PE), Sermoneta (LT) and Trezzano Rosa (MI) and abroad in Tortosa in Spain and in Shreveport (Louisiana) in the United States. The R&D laboratories are in Pomezia and in the Parco Scientifico Tecnologico Kilometro Rosso in Bergamo. Alfasigma’s mission is to improve people’s health and quality of life by offering caregivers and healthcare personnel therapeutic solutions according to the highest standards of quality and safety.
For more information visit: https://www.alfasigma.com/.
Related information
Open Pharma
Online: https://www.openpharma.blog/
LinkedIn: www.linkedin.com/showcase/open-pharma
Bluesky: https://bsky.app/profile/openpharma.bsky.social
YouTube: www.youtube.com/@openpharma6043
Figshare: openpharma.figshare.com
Alfasigma
LinkedIn: https://www.linkedin.com/company/alfasigma/
Twitter/X: https://twitter.com/alfasigmaspa
YouTube: https://www.youtube.com/channel/UCD10IuhShw9pNOBZp-EYdyw
Facebook: https://www.facebook.com/AlfasigmaSPA/
Instagram: https://www.instagram.com/alfasigma_spa/
